Blood Cancer Talks
Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin
Jun 9, 2024
Dr. Benjamin Derman and Dr. Manni Mohyuddin discuss updates in Minimal Residual Disease (MRD) in multiple myeloma, including the potential use of MRD as a surrogate endpoint for accelerated FDA approval. They explore the benefits and challenges of achieving MRD negativity, advancements in MRD detection technologies, implications of MRD resurgence, and the impact of MRD negativity on treatment decisions and discontinuation. The podcast sheds light on the complexities of utilizing MRD in myeloma treatment strategies.
57:48
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- MRD negativity is a prognostic biomarker in myeloma, guiding treatment modifications for better outcomes.
- MRD resurgence kinetics and trials like MRD2STOP inform decisions on maintenance therapy continuation or cessation.
Deep dives
Overview of MRD or Minimal Residual Disease in Multiple Myeloma
Minimal residual disease (MRD) has gained attention in multiple myeloma, with recent advancements discussed in the podcast. MRD negativity correlates positively with better outcomes, serving as a prognostic biomarker and a tool for treatment modification. The significance of individual and trial-level surrogacy of MRD in myeloma is highlighted, showcasing its value as a predictive indicator for patient outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
